Pilot field trial of the EG95 vaccine against ovine cystic echinococcosis in Rio Negro, Argentina: 8 years of work

Larrieu, Edmundo; Mujica, Guillermo; Araya, Daniel; Labanchi, José Luis; Arezo, Marcos; Herrero, Eduardo; Santillán, Graciela; Vizcaychipi, Katherina A.; Uchiumi, Leonardo; Salvitti, Juan Carlos; Grizmado, Claudia; Calabró, Arnoldo; Talmón, Gabriel; Sepúlveda, Luís; Galván, José María Moreno; Cabrera, Marta; Seleiman, Marcos; Crowley, Pablo; Céspedes, Graciela; Cachau, Mariela García; Gino, Lilia Mabel; Molina, Leonardo; Daffner, J. F.; Gauci, Charles G.; Donadeu, Meritxell; Lightowlers, Marshall W.

doi:10.1016/j.actatropica.2018.12.025

Cited by 31 publications

(53 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…On the other hand, the diagnosis and treatment of CE in humans have experienced big changes such as the use of ultrasound and other imaging diagnosis techniques, and the albendazole or PAIR use. These advances have allowed not only an early and quick diagnosis of CE but also the initiation of ALB or PAIR treatment instead of operating many cases that might not be necessary (Brunetti et al, ; Frider & Larrieu, ; Larrieu et al, ; Larrieu, Mujica, et al, ; Larrieu, Uchiumi, et al, ). Active surveillance seeking for human CE cases is an obligation in every prevention and control programme.…”

Section: Resultsmentioning

confidence: 99%

“…Regarding to the farms, 94.7% had at least one positive animal by necropsy in 2009, whereas only 23.5% of them were positive in 2015 (Larrieu et al, ). Using coproELISA for diagnosis of infection in dogs, the differences were statistically significant ( p value = .04) between baseline (2009) and impact (2017) studies in the proportion of positive samples, and in relation to the farms, the differences were not significant among producers with farms with active transmission (by the presence of an infected dog; p value = .1) (Larrieu, Mujica, et al, ; Larrieu, Uchiumi, et al, ).…”

Section: General Principles For Controlmentioning

confidence: 99%

“…Full vaccination was considered to involve two immunizations in lambs and one additional vaccination when the animals were approximately 1 year of age. This being the case, three immunizations at a compliance rate of 80%–85% for each vaccination represents an effective vaccination compliance of 57.3% (Larrieu, Mujica, et al, ; Larrieu, Uchiumi, et al, ).…”

Section: General Principles For Controlmentioning

confidence: 99%

“…Although the EG95 vaccine has demonstrated a high efficacy, there have been few studies that have evaluated the effectiveness of the vaccine under field conditions (Larrieu, Mujica, et al, ; Larrieu et al, ; Larrieu, Uchiumi, et al, ). Additional studies of vaccination are required; for example, it is necessary to look for different vaccination schemes (only lamb vaccination, whole sheep population vaccination); also, animal species involved in the vaccination programme (bovine, goats, pigs and camelids) considering costs of the vaccine and the costs of its placement in the field.…”

Section: General Principles For Controlmentioning

confidence: 99%

“…While echinococcosis is primarily a human health problem, it is necessary to establish vigilance systems of the infection in man, especially in children (between 0/10 years old) or schoolchildren (between 6 and 14 years old), which can be efficiently carried out by using ultrasound (US) screenings (Frider et al, 2000;Larrieu et al, 2011;Perez et al, 2006). Early detection of CE children might facilitate the beginning of albendazole treatment (Brunetti et al, 2011;Frider & Larrieu, 2010;Larrieu, Mujica, et al, 2019;Larrieu, Uchiumi, et al, 2019;Zanini, Suárez, Pérez, & Elissondo, 2009).…”

Section: Surveillance In Humansmentioning

confidence: 99%

See 4 more Smart Citations

Control of cystic echinococcosis: Background and prospects

Larrieu

Gavidia

Lightowlers

2019

Zoonoses and Public Health

Self Cite

View full text Add to dashboard Cite

Cystic echinococcosis (CE), caused by Echinococcus granulosus, is a chronic and debilitating zoonotic larval cestode infection in humans, which is principally transmitted between dogs and domestic livestock, particularly sheep. Human CE occurs in almost all pastoral communities and rangeland areas of the underdeveloped and developed world. Control programmes against CE have been implemented in several endemic countries to reduce or eliminate the disease. New Zealand and Tasmania are examples of some of the first programmes to be undertaken (in insular territories) and which were very successful in the elimination of CE. The advent and proven effectiveness of praziquantel, plus the experience of insular models, produced high expectations for rapid advances in a second generation of control programmes undertaken in continental areas (Argentina, Uruguay and Chile). Nevertheless, only moderate gains in CE control have been made and the impact on prevalence among humans has been slight. A major impediment to the adoption of procedures that were successful in New Zealand and Tasmania has been the requirement to administer praziquantel to dogs in rural areas eight times per year over numerous years. In addition, there have been clear technological improvements made in the diagnosis of canine echinococcosis for surveillance, the genetic characterization of parasite strains and in vaccination against CE infection in livestock. In order to establish new paradigms and appropriate combinations of control strategies, we have carried out a review and discussion of the available control tools and control models. Control strategies must be suitable and sustainable to benefit the Echinococcosis–endemic areas primarily, which at the same time are the poorest regions of the world.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: General Principles For Controlmentioning

confidence: 99%

Section: General Principles For Controlmentioning

confidence: 99%

Section: General Principles For Controlmentioning

confidence: 99%

Section: Surveillance In Humansmentioning

confidence: 99%

See 3 more Smart Citations

Control of cystic echinococcosis: Background and prospects

Larrieu

Gavidia

Lightowlers

2019

Zoonoses and Public Health

Self Cite

View full text Add to dashboard Cite

show abstract

Identification of B‐cell dominant epitopes in the recombinant protein P29 from Echinococcus granulosus

Zhang

et al. 2022

Immunity Inflam & Disease

View full text Add to dashboard Cite

Introduction Echinococcus granulosus (E. granulosus) causes a hazardous zoonotic parasitic disease. This parasite can occupy the liver and several areas of the body, causing incurable damage. Our previous studies have provided evidence that the recombinant protein P29 (rEg.P29) exhibit immune protection in sheep and mice against pathological damage induced by E. granulosus, showing its potential as candidate for vaccine development. However, information on the B‐cell epitopes of rEg.P29 has not yet been reported. Methods Immunological model was established in mice with rEg.P29. SDS‐PAGE and Western blot were used to identify protein. Screening for B‐cell dominant epitope peptides of rEg.P29 by enzyme‐linked immunosorbent assay (ELISA) and immune serum. Dominant epitopes were validated using ELISA and flow cytometry. Multiple sequence alignment analysis was performed using BLAST and UniProt. Results Immunization with rEg.P29 induced intense and persistent antibody responses, and the epitope of the dominant antigen of B cells are identified as rEg.P29166–185 (LKNAKTAEQKAKWEAEVRKD). Anti‐rEg.P29166–185‐specific antibodies lack epitopes against IgA, IgE, and IgG3, compared to anti‐rEg.P29‐specific antibodies. However, anti‐rEg.P29166–185 IgG showed comparatively higher titers, as determined among those peptides by endpoint titration. In addition, rEg.P29 and rEg.P29166–185 promote B‐cell activation and proliferation in vitro. The dominant epitopes are relatively conserved in different subtypes of the rEg.P29 sequence. Conclusion rEg.P29166–185 can act as a dominant B‐cell epitope for rEg.P29 and promote cell activation and proliferation in the same way as rEg.P29.

show abstract

Echinococcus Species: Tiny Tapeworms

Mehlhorn

2020

Parasitology Research Monographs

View full text Add to dashboard Cite

Pilot field trial of the EG95 vaccine against ovine cystic echinococcosis in Rio Negro, Argentina: 8 years of work

Cited by 31 publications

References 14 publications

Control of cystic echinococcosis: Background and prospects

Control of cystic echinococcosis: Background and prospects

Identification of B‐cell dominant epitopes in the recombinant protein P29 from Echinococcus granulosus

Echinococcus Species: Tiny Tapeworms

Contact Info

Product

Resources

About